SanegeneBio Announces First Patient Dosed in Phase 1 Trial of SGB-7342
Jan 13, 2026
BOSTON, SHANGHAI, and SUZHOU – January 13, 2026, SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, announced that the first patient has recently been dosed in a Phase 1 clinical trial of SGB-7342 at the first hospital of Jilin University in China. This randomized, double-blind, placebo controlled, single ascending dose Phase 1 clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SGB-7342 in overweight and obese patients.
SGB-7342 is an investigational GalNAc-conjugated siRNA medicine for the treatment of obesity targeting Inhibin Beta E (INHBE) messenger RNA (mRNA) in hepatocytes. It incorporates SanegeneBio's proprietary GalNAc configuration and oligonucleotide chemistry, which has resulted in potentially best-in-class Phase 1 performance for several other recent investigational siRNA medicines. SGB-7342 is designed to silence the INHBE gene through an RNAi mechanism, thereby reducing circulating Activin E levels and inhibiting downstream signaling pathways involved in lipid metabolism and energy expenditure. In preclinical studies, SGB-7342 demonstrated robust INHBE silencing, loss of body weight and fat mass, preservation of lean mass, and a favorable safety and tolerability profile.
Dr. Yuyan Jin, Senior Vice President of Clinical and Nonclinical Development at SanegeneBio, stated:
About SanegeneBio
SanegeneBio is a global, venture-backed, fully-integrated biotechnology company focused on developing RNAi-based therapeutics. Founded in 2021 and led by a team of RNAi veterans, the company has R&D operations in Boston, Shanghai and Suzhou. Their clear vision is that RNAi technology will power blockbuster medicines in diverse therapeutic areas, improving the quality and longevity of life for patients worldwide. This vision is being realized by advancing a fast-growing pipeline, which includes experimental medicines for autoimmune nephropathies, obesity, and cardiometabolic indications. SanegeneBio has initiated clinical trials for four experimental medicines to-date, and is committed to developing potential best-in-class and first-in-class therapeutics which leverage our industry-leading and differentiated LEAD™ tissue-selective RNAi delivery technology. For more information, please visit: www.sanegenebio.com and engage on LinkedIn.
Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. Any statements in this release other than statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "could," "potential," "is/are likely to," "will," "plan," "intend," "aim," "expect," "anticipate," "believe," "hope," "estimate," "project," "forecast," "continue," "target," and similar expressions (or the negative of these terms) are intended to identify forward-looking statements. In addition, statements that refer to future results, trends in our business, expectations for our product pipeline or product candidates, or other characterizations of future events or circumstances are forward-looking statements.
These forward-looking statements are based on our current expectations and assumptions as of the date of this news release and speak only as of such date. They are not guarantees of future performance, and actual results may differ materially from those expressed or implied by forward-looking statements due to a variety of risks and uncertainties, many of which are beyond our control. These risks and uncertainties include, without limitation: risks in research and development and clinical trials; regulatory review, requirements, and timing; trial initiation, site activation, enrollment, and operational execution (including performance by third parties); manufacturing, supply, and quality risks; the impact of competition and new technologies; future market conditions; macroeconomic, political, legal, and social conditions; and our ability to obtain and maintain sufficient funding and other resources. Readers are cautioned not to place undue reliance on these forward-looking statements. We assume no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise, except as required by applicable law.
Medical Information
This press release is provided for informational purposes only and is intended to share scientific and disease-related information. It is not intended as advertising or commercial promotion of any product and does not constitute medical advice, a diagnosis, or a recommendation for any treatment or use of any product. For questions about medical conditions or treatment, please seek advice from a healthcare professional.